ArticleBMJ open2022

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.

Sadahisa Ogasawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.